跳至主要内容
临床试验/NCT00630175
NCT00630175已完成3 期

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia. A Double-Blind, Randomized, Placebo-Controlled,Three Way Cross-Over Study

Sanofi3 个研究点 分布在 3 个国家目标入组 113 人开始时间: 2003年9月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Sanofi
入组人数
113
试验地点
3
主要终点
Polysommography (PSG) wake time after sleep onset (WASO)

研究概览

简要总结

The primary objective is to evaluate the hypnotic efficacy of zolpidem-MR (modified release) 12.5 mg and zolpidem 10 mg marketed product in comparison with placebo in patients with primary insomnia and sleep maintenance difficulties, using polysomnography (PSG) recordings and patient sleep questionnaires.

The secondary objective is to evaluate the clinical safety and tolerability of zolpidem-MR 12.5 mg and zolpidem 10 mg marketed product in comparison with placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria

排除标准

  • 未提供

结局指标

主要结局

Polysommography (PSG) wake time after sleep onset (WASO)

次要结局

  • PSG parameters, Patient's sleep questionnaire, Patient's global impression, Relative degree of satisfaction with the different study drugs

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (3)

Loading locations...

相似试验